What is Eloralintide?
Eloralintide (MEDI0382) is a dual GLP-1R and GCGR (glucagon receptor) co-agonist developed by AstraZeneca/MedImmune. Unlike tirzepatide (GIP+GLP-1), eloralintide pairs GLP-1R with GCGR — the glucagon receptor agonism component drives thermogenesis, fatty acid oxidation, and hepatic glucose modulation. Phase 2 clinical data demonstrated significant weight loss and metabolic improvements in T2DM patients. Research tool for GLP-1R/GCGR dual pharmacology and comparison with triple (GIP+GLP-1+GCG) agonists like retatrutide. Research use only.
Research Applications
Dual GLP-1R/GCGR Pharmacology
GLP-1 + glucagon receptor co-agonism — receptor synergy, cAMP signalling, selectivity profiling
GCGR vs GIPR Comparison
Eloralintide (GLP-1+GCGR) vs tirzepatide (GLP-1+GIP) — differential receptor contribution studies
Hepatic Fat & NASH
GCGR-mediated hepatic fat reduction, liver steatosis, and NASH model research
Metabolic Disease Research
Weight loss, insulin secretion, glucagon suppression, T2DM models
Incretin + Glucagon Biology
Combined GLP-1 + glucagon receptor biology — energy expenditure and thermogenesis
Quick Specs
| Form | Synthetic peptide dual agonist — sequence-specific |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not publicly standardized (MEDI0382) |
| Molecular Weight | MS molecular weight confirmed — every batch |
| Specification | ≥99% by HPLC — every batch |
| Shelf Life | 24 months (unopened) |
| Storage | −20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Brand | China |